ALX Oncology Q2 2026 net loss $18.0M; cash $153.4M; refinances debt facility

ALX ONCOLOGY HOLDINGS INC

GAAP net loss of $18.0M ($0.13/share) vs $25.9M ($0.49/share) in Q2 2025; non-GAAP net loss $14.3M.
Cash, equivalents and investments $153.4M; sufficient to fund operations through H1 2028.
Refinanced $10M debt with HSBC Ventures; can draw up to additional $20M through June 2028; total facility up to $50M.
Appointed Scott Garland as Chairman and Michael Listgarten as General Counsel.
ASPEN-09-Breast Phase 2 topline data from 80 patients expected mid-2027; ALX2004 safety data expected 2H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.